Ambitious Danish biotech fund shuts down before first investment

Ambitions were high when Sund Capital, headed by the former Zealand Pharma CEO David Solomon, announced plans to raise up to DKK 2 billion (EUR 268 million) for investments in up-and-coming biotechs. But now the fund is closing down.
Former Zeland Pharma CEO David Solomon was co-founder of the venture fund Sund Capital
Former Zeland Pharma CEO David Solomon was co-founder of the venture fund Sund Capital
Mikkel Aabenhus Hemmingsen

With a total loss of DKK 2.9 million after 18 months, the end has come for Sund Capital which was founded in summer 2016 with the aim of investing up to DKK 2.2 billion in Nordic biotechs.

Already a subscriber?Log in here

Read the whole article

Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

With your free trial you get:

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
!
!
Must contain at least 6 characters
!
Must contain at least 2 characters
!
Must contain at least 2 characters

Get full access for you and your coworkers

Start a free company trial today

Sign up for our newsletter

Stay ahead of development by receiving our newsletter on the latest sector knowledge.

!
Newsletter terms

Front page now

Further reading

Influencers that advise on financial products have drawn the attention of the European Commissioner for financial services, Mairead McGuinness. | Foto: Aurore Martignoni / European Union

EU to crack down on "finfluencers"

For subscribers